HLA-DQA1/DQB1 duplex genotyping assay
Celiac disease is associated with certain HLA-DQA1 and HLA-DQB1 loci. At GenDx, we are developing a DQA1/DQB1 assay which is compatible with Oxford Nanopore Technologies and Illumina sequencing devices. This duplex assay is designed to amplify both HLA-DQA1 and HLA-DQB1 in the same reaction, making it faster and more efficient to study both genes together.
Celiac disease is an immune-mediated disorder triggered by gluten ingestion in genetically susceptible individuals. It is strongly associated with specific alleles of the HLA-DQA1 and HLA-DQB1 genes, which encode the alpha and beta chains of the HLA-DQ heterodimer. This heterodimer is involved in presenting gluten-derived peptides to T cells, a key step in the immune response leading to the characteristic intestinal damage seen in celiac disease.
To support research in this area, we are developing a DQA1/DQB1 duplex assay that enables whole-gene coverage of both loci in a single workflow. This upcoming assay is designed to be compatible with both Oxford Nanopore Technologies and Illumina sequencing platforms, offering flexible integration into existing sequencing pipelines.
Identify genetic risk for celiac disease with high-resolution typing of HLA-DQA and HLA-DQB loci.
Our upcoming DQA1/DQB1 duplex assay is designed for comprehensive whole-gene coverage of both HLA-DQA1 and HLA-DQB1—key loci associated with celiac disease susceptibility.
Key features
Whole-gene coverage of both DQA1 and DQB1 loci
Duplex design – genotype both genes in a single reaction
96-sample throughput per run
Same-day results when using Oxford Nanopore Technologies platforms
Compatible with both Oxford Nanopore Technologies and Illumina sequencing platforms
Whether you prefer long-read or short-read sequencing, this assay integrates seamlessly into your workflow, delivering high-quality data with rapid turnaround.
Currently in development.
Want to stay informed? Join our product updates list or contact your Sales representative for more information.
